20 October 2020 in Journal of Clinical Oncology
MGMaria V. Grau-Sepulveda
+2
PURPOSE: We examined the relationship between short-term outcomes and hospitals and surgeons who met minimum volume thresholds for lung cancer resection based on definitions provided by the Volume Pledge. A secondary aim was to evaluate the volume-outcome relationship to determine alternative thresholds in the event the Volume Pledge was not associated with outcomes.PATIENTS AND METHODS: We conducted a retrospective study (2015-2017) using the Society of Thoracic Surgeons General Thoracic Surgery Database. We used generalized estimating equations that accounted for confounding and clustering to compare outcomes across hospitals and surgeons who did and did not meet the Volume Pledge criteria: ≥ 40 patients per year for hospitals and ≥ 20 patients per year for surgeons. Our secondary aim was to model volume by using restricted cubic splines to determine the association between volume and short-term outcomes.RESULTS: Among 32,183 patients, 465 surgeons, and 209 hospitals, 16,630 patients (52%) received care from both a hospital and surgeon meeting the Volume Pledge criteria. After adjustment, there was no relationship with operative mortality, complications, major morbidity, a major morbidity-mortality composite end point, or failure to rescue. The Volume Pledge group had a 0.5 day (95% CI, 0.2 to 0.7 day) shorter length of stay. Our secondary aim revealed a nonlinear relationship between hospital volume and complications in which intermediate-volume hospitals had the highest risk of complications. Surgeon volume was associated with major morbidity, a major morbidity-mortality composite end point, and length of stay in an inverse linear fashion. Only 8% of surgeons had volumes associated with better outcomes.CONCLUSION: The Volume Pledge was not associated with better outcomes except for a marginally shorter length of stay. A re-examination of volume-outcome relationships for hospitals and surgeons yielded mixed results that did not reveal a practical alternative for volume-based quality improvement efforts.
29 November 2021 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES: Shortening hospital length of stay after lobectomy for stage I non-small-cell lung cancer (NSCLC) remains a challenge, and the literature regarding factors associated with safe early discharge is limited. We sought to evaluate the safety of postoperative day (POD) 1 discharge after lobectomy and its correlation with institutional caseload using the National Cancer Database, jointly sponsored by the American College of Surgeons and the American Cancer Society. METHODS: We identified patients with stage I NSCLC (tumour ≤4 cm, clinical N0, M0) in the National Cancer Database who underwent lobectomy from 2010 to 2015. Hospital surgical volume was assigned based on total surgical volume for lung cancer. The cohort was divided into 2 groups: POD 1 discharge [length of stay (LOS) ≤ 1] and the standard discharge (LOS > 1). Outcome variables were compared in propensity matched cohorts, and the multivariable regression model was created to assess factors associated with LOS ≤ 1 and the occurrence of adverse events (unplanned readmissions, 30- and 90-day deaths). RESULTS: A total of 52 830 patients underwent lobectomy for stage I NSCLC across 1231 treating facilities; 3879 (7.3%) patients were discharged on day 1 (LOS ≤ 1), whereas 48 951 (92.7%) were discharged after day 1 (LOS > 1). Factors associated with LOS ≤ 1 included male sex, higher socioeconomic status, right middle lobectomy, minimally invasive surgery and high-volume centres. The risk of adverse events was higher for LOS ≤ 1 in low [odds ratio (OR): 1.913, 95% confidence interval (CI) 1.448–2.527; P < 0.001] and median quartiles (OR: 2.258; 95% CI 1.881–2.711; P < 0.001), but equivalent in high-volume centres (OR: 0.871, 95% CI 0.556–1.364; P = 0.54). CONCLUSIONS: The safety and efficacy of early discharge on POD 1 following lobectomy are associated with lung cancer surgical volume. Implementation of ‘enhanced recovery’ protocols is likely related to safe early discharges from high-volume centres.
25 September 2024 in Journal of Clinical and Translational Pathology
Tumor molecular analysis using next-generation sequencing (NGS) is the standard of care for guiding lung cancer treatment. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique used to sample mediastinal lymph nodes for diagnosing and staging lung cancer. This study aimed to determine if EBUS-TBNA provided adequate tissue samples for NGS.
1 August 2025 in Annals of the American Thoracic Society
Rationale: Percent predicted forced expiratory volume in 1 second (FEV1pp) is used for surgical risk assessment in patients with lung cancer. FEV1pp is adjusted for race, despite concerns regarding inaccurate estimations of lung health. Objectives: To compare prediction of race-specific versus race-neutral FEV1pp for pulmonary complications after lung cancer resection. Methods: Patients who underwent lung resection in the Society of Thoracic Surgeons General Thoracic Surgery Database were identified (2002–2008). We used Global Lung Initiative equations to derive race-specific and race-neutral FEV1pp and compared their performance to predict pulmonary complications. Postoperative FEV1pp was calculated with patients categorized into low- (>60%), intermediate- (30–60%), and high- (<30%) risk groups. Results: Of 24,276 patients, most were White (n = 21,130; 87.0%) or Black (n = 1,912; 7.9%). Race-specific equations reduced the mean FEV1pp by 5.3% for White patients and increased it 6.2% for Black patients compared with race-neutral equations. Multivariate models using race-neutral FEV1pp performed similarly to race-specific models in predicting pulmonary complications (sublobar resection: C-statistic 0.72; lobectomy: C-statistic 0.65; and bilobectomy/pneumonectomy: C-statistic 0.67; for both models) with similar adjusted odds ratios of FEV1pp for both equation types. In 5,422 patients with calculable postoperative FEV1pp, 617 (11.4%) were recategorized into a higher (n = 65) or lower (n = 552) risk group when using race-neutral equations. Of those moving into a lower-risk group, 98.0% were White. All patients reclassified into higher-risk groups were Black. Conclusions: Race-neutral FEV1pp performed equally well as race-specific equations in predicting pulmonary complications and disentangled the effect of respiratory function from race on outcomes.